Podcasts about Injection

Could something as simple as a 20-minute bike ride improve the quality of platelet-rich plasma?In this episode of Overtime with The Sports Docs, Drs. Ashley Bassett and Catherine Logan explore an intriguing laboratory study examining whether exercise performed immediately before a PRP blood draw can enhance the cellular composition of platelet-rich plasma.As biologic therapies continue to expand throughout sports medicine, optimizing PRP has become increasingly important. While most discussions focus on centrifuge systems, platelet concentrations, leukocyte content, and injection techniques, this study introduces another potential variable: the patient.The authors found that a brief bout of vigorous exercise significantly increased platelet concentrations and mobilized hematopoietic progenitor cells, raising the possibility that exercise could serve as a simple, low-cost strategy to optimize biologic treatments.In This Episode, We Discuss: The fundamentals of PRP and how it works  Why PRP variability remains one of the biggest challenges in interpreting the literature  Conditions with the strongest evidence supporting PRP:  Knee osteoarthritis  Lateral epicondylitis  Patellar tendinopathy  Plantar fasciitis  The concept of exercise-mobilized PRP  Differences between plasma-based and buffy coat PRP systems  Whether higher platelet concentrations actually translate into improved clinical outcomes  How this research may influence real-world PRP protocols Study BreakdownStudy Design: Prospective laboratory studyParticipants: 20 healthy volunteers (ages 21–45 years)Exercise Protocol: 5-minute warm-up  20 minutes of cycling  Target heart rate: 70–85% of predicted maximum Blood samples were obtained before and immediately after exercise and processed using two PRP systems:ACP System (plasma-based PRP) Angel System (buffy coat PRP) Key FindingsWhole Blood Changes After Exercise Platelet count increased approximately 22% White blood cell count increased approximately 50%ACP System Platelet concentration increased from approximately: 457,000/µL → 562,000/µLAngel System Platelet concentration increased from approximately: 2.95 million/µL → 3.77 million/µL PRP volume increased  Hematopoietic progenitor cell concentrations increased significantly Why This MattersThe study suggests that patient physiology before blood collection may significantly influence the final biologic product.A brief exercise session may: Increase platelet yield  Mobilize progenitor cells  Potentially enhance biologic activity  Provide a low-cost method to optimize PRP preparation For clinicians performing biologic injections, exercise may become another controllable variable alongside: PRP preparation system  Centrifuge settings  Leukocyte concentration  Injection technique Clinical Pearls✔ PRP is not a single product. Composition varies substantially between systems.✔ Patient factors may influence PRP quality just as much as centrifuge settings.✔ Twenty minutes of exercise increased platelet concentrations in both PRP systems.✔ Buffy coat systems demonstrated increased progenitor cell concentrations.✔ The clinical significance of these changes remains unknown.The Big QuestionDoes exercise-enhanced PRP actually improve patient outcomes?This study demonstrates changes in laboratory measurements, but it does not tell us whether patients: Heal faster  Experience less pain  Return to sport sooner  Demonstrate better tendon or cartilage healing Future studies are needed to determine: Optimal exercise type  Ideal exercise intensity  Timing before blood draw  Which conditions benefit most Dr. Logan's Clinical PerspectiveAt the Joint Preservation Center, this study has prompted discussions about incorporating pre-injection exercise into PRP protocols. A simple 20-minute cycling session before blood collection may represent a practical strategy to optimize a patient's own biology before treatment.While additional evidence is needed, this concept aligns with the broader goal of maximizing the effectiveness of biologic therapies through thoughtful patient preparation.Take-Home Points Exercise before PRP collection significantly increases platelet concentrations.  Short bouts of exercise may mobilize progenitor cells.  Patient physiology may influence PRP composition.  Exercise represents a low-cost, non-pharmacologic optimization strategy.  More research is needed to determine whether these laboratory changes improve clinical outcomes. Resources Mentioned Episode #161: Platelet concentration and outcomes following PRP for lateral epicondylitis  Recent Sports Docs episode with Dr. Arianna Gianakos discussing PRP for plantar fasciitis 

A lesson in universal love, told via deep club grooves. When future heads look back at New York nightlife from the mid-2010s onwards, the name Love Injection will stand out. As historians, stewards and disciples of underground dance music, Barbie Bertisch and Paul Raffaele live and breathe the culture's inclusive, anti-commercial and anti-egotistical ideals. Underlining their myriad pursuits–DJing, promoting, publishing, curation, the list goes on–are ironclad principles destined to cement their legacy. On RA.1044, the duo keep it real. Recorded spontaneously, it shows off their core palette: timeless Detroit house courtesy of Scott Grooves, leftfield 303 squelches from Magic Mountain High, the classic dub techno of Rhythm & Sound and plenty more besides. It's a living history of Love Injection, delivered with their signature level of passion and care. Find the tracklist and Q&A at ra.co/podcast/1063

Jonathan Rodriguez Cefalu built the hardware that Snap shipped on people's faces — first the camera-only Gen 1 Spectacles, then the Gen 4 display version. His path through Stanford CS, an honors thesis on varifocal display optics, and a startup called Vergence (named after the vergence-accommodation conflict in AR) led him to Snap, and then to the problem he is working on now. Preamble AI exists to prevent the worst possible AI outcomes — starting with a class of attack that Preamble was the first to publicly demonstrate: prompt injection.Ted Schilowitz hosted this episode solo. Together, he and Jonathan worked through the architecture problem sitting under every AI assistant being deployed at scale right now: large language models see one token stream. There is no separation between what the developer intended and what an untrusted email or web page is quietly instructing the model to do. With Gemini Spark about to give AI agents access to tens of thousands of emails per user, this is not a theoretical concern. Jonathan's team has a proposed fix — and they have already shaped federal law.The episode also covered the week's XR and AI news: Google I/O announcements, Snap Spectacles Gen 6 details ahead of AWE, Matthew Ball joining Xbox, Anduril's battlefield AR wearable, and AI-generated feature films reaching Tribeca.Key Moments:[00:00] Ted opens solo — Charlie Fink and Rony Abovitz are out for the summer solstice[02:30] Google I/O: Gemini Spark and what "persistent AI agent" actually means in practice[08:15] Jonathan's Gmail test: asked to search tens of thousands of emails, it searched 30 and quit[14:40] XREAL Project Aura and the state of Android XR — a lot of spend for incremental steps[21:00] Snap Spectacles Gen 6 details: what Jonathan knows from building Gen 1 and Gen 4 from the inside[31:20] Snap vs. Meta: research that ships in the product vs. research that ships in a paper[38:45] Matthew Ball joins Xbox, Anduril EagleEyes, and battlefield AR wearables[44:10] AI on the Lot: Project Nara, Hell Grind, Dreams of Violet, Paul Schrader goes pro-AI[52:30] Jonathan introduces Preamble AI and the mission to prevent worst-case AI outcomes[58:00] The first public demonstration of prompt injection — what happened and why it matters[01:06:15] Why Gemini Spark will be especially vulnerable to prompt injection attacks[01:14:00] Preamble's proposed fix: a reserved token language that untrusted data cannot speak[01:21:30] NDAA Section 1638: the first US law making it illegal to give AI autonomous nuclear control[01:28:45] WarGames, "the only winning move is not to play," and what that means in 2026Brought to you by Zappar and Mattercraft. Mattercraft makes spatial web experiences that run in the browser — no app required. Visit mattercraft.io to learn more and start building. Hosted on Acast. See acast.com/privacy for more information.

An injection can take away your sciatica, but it doesn't heal the injury causing it — and that distinction decides whether you get better.If you've had, or you're being offered, a steroid injection, epidural or nerve block for sciatica or a herniated disc (a slipped disc or disc bulge) at L4/L5 or L5/S1, this session reframes the whole decision around one question: what is this injection doing to help my injury heal, not just my pain? Get that right and an injection can be a useful tool. Get it wrong and it's a mask — the pain lifts, you carry on as before, and the injury that caused it is still there.

Japanese startup Heartseed Inc. has said it conducted a clinical trial to inject via catheter small masses of heart muscle cells produced from induced pluripotent stem, or iPS, cells into patients with severe heart failure.

Il y a une semaine, l'Afrique du Sud lançait officiellement le lénacapavir, un antirétroviral utilisé dans le traitement de l'infection par le VIH, jugé révolutionnaire. Avec une seule injection tous les six mois, ce médicament préventif atteint une efficacité qui frôle les 100%. « Un signe d'espoir » s'est réjoui Cyril Ramaphosa, président du pays le plus touché au monde par le VIH, avec plus d'un Sud-Africain sur dix porteurs du virus. Un signe d'espoir également pour toute l'Afrique, qui concentrait, en 2024, 65% des personnes vivant avec le VIH dans le monde, selon les données d'Onusida. La Camerounaise Ndong Essomba Bitchoka, infectiologue à l'unité de prise en charge des patients VIH/SIDA à l'hôpital de Deido, à Douala explique ce que ce traitement peut changer.    RFI : Les Sud-Africains porteurs du VIH peuvent désormais bénéficier du nouveau traitement Lenacapavir. Pourriez-vous expliquer comment fonctionne ce traitement ? Dr Ndong Essomba Bitchoka : Le Lenacapavir est un médicament antirétroviral. Il va empêcher l'assemblage des molécules ARN du virus du VIH, donc empêcher la formation de nouveaux virus du VIH. C'est à peu près comme ça qu'il fonctionne. Pour simplifier un peu, quelle est la grande avancée du Lenacapavir par rapport à la PrEP, le traitement le plus couramment utilisé ? La PrEP est un médicament qu'on va administrer aux personnes non-infectées au VIH pour leur éviter de le contracter. Il est beaucoup plus indiqué pour les personnes qui sont plus à risque de développer le VIH. Le Lenacapavir, par contre, peut être utilisé dans le traitement de l'infection au VIH pour contrôler le virus chez certaines personnes. C'est-à-dire qu'au lieu de prendre des comprimés tous les jours par exemple, vous allez avoir des injections qui vont permettre de limiter la réplication du virus dans votre organisme pendant environ six mois. Donc la PrEP est destinée à titre préventif aux personnes non-porteuses du VIH, tandis que le Lenacapavir peut aussi être un traitement pour les personnes porteuses. Et sa grande différence est qu'au lieu de comprimés, on donne des injections deux fois par an… Exactement ! La personne doit déjà au préalable être contrôlée avec des médicaments oraux, avec des comprimés. Puis le Lenacapavir vient appuyer l'action des antirétroviraux qui étaient déjà présents à la base, qui contrôlaient le virus. Sauf que ce même contrôle va se faire sur une longue durée d'action associée à d'autres médicaments. Donc le Lenacapavir pour une personne déjà porteuse du VIH, il faut déjà qu'il y ait un traitement antérieur au Lenacapavir ? C'est cela. Si on a un patient qui est dépisté séropositif au VIH aujourd'hui, le Lenacapavir ne sera pas la première intention qu'on pourra lui proposer en termes de traitement. Hormis l'Afrique du Sud qui cumule le plus grand nombre de personnes atteintes du VIH dans le monde (8 millions de Sud-Africains, NDLR), une grande partie des infectés vivent en Afrique. Vous avez une estimation du coût du traitement ? Comme je n'ai pas le coût exact, je ne pourrai pas vous donner une réponse exacte. Mais dans la majorité des cas, si je parle par exemple de mon pays, le Cameroun, le Lenacapavir n'est pas encore accessible par exemple. Mais pour l'instant, les États avec les partenaires financiers font le nécessaire pour que les médicaments soient subventionnés. Du coup, les patients ne les paient pas. Dans le cas de l'Afrique du Sud, je ne sais pas encore si ce sera le cas ou pas, mais je pense que les États se battent pour voir dans quelle mesure subventionner, ne serait-ce qu'en partie, l'accès à ces médicaments antirétroviraux. Pour l'instant, seules 40 000 doses ont été mises à disposition en Afrique du Sud. Le président Cyril Ramaphosa annonce la fourniture d'un million de doses d'ici fin 2027. Sauf que l'organisation Health Gap estime qu'il en faudrait le double de ces doses chaque année pour répondre aux besoins du pays. Au-delà du cas sud-africain, une pénurie plongerait-elle les patients bénéficiaires dans un nouveau désarroi ? Quelles seraient les conséquences s'ils étaient forcés de suspendre le traitement ? C'est bien de pouvoir commencer avec un certain nombre de doses et de sélectionner les patients qui sont vraiment nécessiteux par rapport à ce traitement au Lenacapavir. En fonction de comment la réponse à ce traitement se fera chez ces patients, on pourrait envisager d'augmenter le nombre de doses disponibles et même d'augmenter la population qui pourrait y avoir accès. Le risque, effectivement, c'est qu'en disponibilisant beaucoup de doses de médicaments et qu'après l'Etat ne puisse plus s'en procurer, ça va effectivement créer une rupture dans le traitement et la survenue de résistance à cet antirétroviral, qui est plutôt salutaire pour la prise en charge des patients. On rappelle que le Lenacapavir n'est pas un vaccin. Pourquoi y a-t-il plus de recherches sur le traitement plutôt que sur un vaccin ? Est-ce si compliqué à élaborer ? Le VIH est un virus qui est un petit peu sournois, dans le sens où il a beaucoup de mutations. Imaginez un cambrioleur qui visite différentes maisons, mais avec un mode opératoire différent. Il est identifié comme mesurant 1m80 quand il frappe dans la maison A, mais quand il va dans la maison B, il mesure plutôt 1m50. Ce qui lui permet d'entrer dans certaines ouvertures inaccessible pour un cambrioleur de 1m80. Il y a beaucoup de mutations. On n'arrive pas encore à identifier un vaccin qui pourrait bloquer l'action de ces différentes souches mutantes du VIH. C'est ce qui rend la chose difficile pour trouver un vaccin. Mais il y a quand même des essais qui donnent un petit peu espoir. Notamment l'essai BRILLIANT 011 en cours justement en Afrique du Sud, pour lequel on espère avoir de bons résultats d'ici quelques années.

♦ Reverse Bass Hardstyle Mix by Hardtonic ♦ June 2026 ♦ 320 kbps Audio ♦ Tracklist: 001 - Ethan Mitchell - Like A Slut (Original Mix) 002 - Condy - Whoomp That Ess (Original Mix) 003 - Swankie DJ & Kashi, Pulsar, Chaos Theory - Bangz Harder (Original Mix) 004 - Distorterz - Pillz (Original Mix) 005 - Staro - MuthaFucka (Original Mix) 006 - Pajaaa18 - Bag Got My Back (Staro Remix) 007 - Julien Dreamheart - Rave Bitch (Original Mix) 008 - Sam Dillon - Scary Dreams (Original Mix) 009 - DV60 - Take This Sound (Original Mix) 010 - DV60 - Into My Mind (Original Mix) 011 - ORREN x SIMOX - Muthafucka (Original Mix) 012 - Toni Knox - Slander & Injury (Original Mix) 013 - Conor Hughes - No Love For The Bass (Original Mix) 014 - Eric Lindsay & CONDY - Rock The Beat (Original Mix) 015 - Condy - My AK (Original Mix) My Fan Page Facebook : www.facebook.com/Hardtonic

DianeKazer.com/SPOOKY2 --> CHIMINISTRY 5% Off Join Our Root Cause Reset Beginning June 18 --> DianeKazer.com/RCR Join Our Elite VIP Tribe for Peptide & Bioregulator Support + Live Q&A -->DianeKazer.com/VIP Apply to Become a One-on-One Patient --> DianeKazer.com/PATIENT SHOW LINKS: https://www.spooky2-mall.com/peptide-presets-revolutionizing-healing-at-the-molecular-level/ https://www.spooky2reviews.com/ https://www.spooky2reviews.com/browse-by-disease/ What if one of the most powerful healing tools isn't a supplement, medication or expensive treatment... But a simple and affordable device you use at home, or anywhere? Over the past year, I've been using a healing tool from home that has completely changed the way I think about supporting the body. It's become an integral part of my own wellness routine, and after receiving so many questions from our community, I decided it was time to bring in expert Spooky2 Trainer, Jon Ellis, to discuss a technology that has developed a passionate following among those looking for natural ways to support their health. During this eye-opening conversation, we'll cover:

In episode 323 of Absolute AppSec, co-hosts Ken Johnson and Seth Law focus heavily on core application security vulnerabilities, legacy operational struggles, and the challenges of generative AI systems. After briefly discussing Seth's recent trip to BSides Vancouver and confirming upcoming conference training logistics for Black Hat and DEF CON, the duo dives into the persistent problem of secrets and sensitive data leaking into log files. Referencing an article and talk by Alan Reyes, they unpack the compounding nature of logging failures, noting how system-level integrations and production error conditions often dump entire object blocks or environment variables into third-party tools. They caution that while pattern-based scanners exist, they remain too brittle to capture complex edge cases, and utilizing expensive AI agents to screen every real-time log line is economically impractical. Transitioning to AI security, Seth explores a multi-page research paper analyzing prompt injection. The paper establishes that because large language models mathematically process data through tokenization without any physical or architectural separation between instructions and data contexts, prompt injection cannot be completely solved at the model level. Likening prompt injection to automated social engineering, they argue that the onus currently falls entirely on developers to implement deterministic validation, guardrails, and secure application-level harnesses.

In this episode of China Manufacturing Decoded, Adrian is joined by Paul Adams, Head of New Product Development at the Sofeast Group's contract manufacturer Agilian Technology, to discuss one of the most common assumptions hardware founders make before moving into tooling: that tooling will take “8 to 12 weeks.” Paul explains why that figure can be true in very simple cases, but why it is often misleading for real consumer electronics, IoT, and hardware products. Tooling timelines depend on design readiness, DFM review, part complexity, steel selection, toolmaker capacity, customer responsiveness, and the timing of Chinese holidays such as Chinese New Year and Golden Week. They also discuss why the tooling clock does not really start when the purchase order is placed, why T0, T1, and T2 trials need to be planned carefully, and why founders should build schedule buffers before cutting steel. For hardware startups and product teams preparing for injection molding, metal stamping, die casting, or other production tooling, this episode explains how to build a more realistic tooling schedule and avoid costly launch delays.   Podcast sections 00:00:31 – The “8 to 12 week tooling timeline” 00:02:28 – What tooling includes and why it matters 00:04:21 – Tooling cost and why first-time founders get caught out 00:06:08 – Where the 8 to 12 week figure comes from 00:07:23 – Why real consumer electronics products are more complex 00:08:35 – When the tooling timer really starts 00:11:10 – Why design readiness and DFM review are critical 00:13:26 – How part complexity affects tooling lead time 00:13:50 – Steel selection: P20, H13, and tool life 00:15:40 – Responsiveness during T0, T1, and T2 trials 00:16:26 – Why being in China can speed up tooling decisions 00:19:03 – Planning around Chinese New Year, Golden Week, and May Day 00:21:47 – How to create a tooling schedule that works 00:22:05 – Reviewing the DFM report properly before cutting steel 00:24:00 – Building a tooling specification and critical path plan 00:25:34 – Understanding T0, T1, T2, and rework cycles 00:27:45 – Why you should always build in a schedule buffer 00:28:56 – Why many tooling delays come from the customer side 00:30:15 – Final advice: understand the full tooling process   Related content Tooling Management for Plastic Injection Molds in China Plastic Injection Mold Tooling Management & Risk Reduction [Podcast] Common Design For Manufacture Improvements On Plastic Injection Molded Parts Injection Mold Tooling Roadmap: How to Get from Smart Design to T1 Samples What are Plastic Injection Mold Tooling Revisions? (3 examples) How To Make Faster Injection Mold Tooling [7 Tips] Plastic Injection Molding Pilot Runs: What You Need To Know The Four Levels of Plastic Injection Molding Suppliers in China Get in touch with us Connect with us on LinkedIn Contact us via Sofeast's contact page Subscribe to our YouTube channel Prefer Facebook? Check us out on FB

Mandy Wiener speaks to founder and editor-in-chief of the Bhekisisa Centre for Health Journalism, Mia Malan about the Lenacapavir HIV prevention injection that being launched by President Ramaphosa for roll out across the country The Midday Report with Mandy Wiener is 702 and CapeTalk’s flagship news show, your hour of essential news radio. The show is podcasted every weekday, allowing you to catch up with a 60-minute weekday wrap of the day's main news. It's packed with fast-paced interviews with the day’s newsmakers, as well as those who can make sense of the news and explain what's happening in your world. All the interviews are podcasted for you to catch up and listen to. Thank you for listening to this podcast of The Midday Report Listen live on weekdays between 12:00 and 13:00 (SA Time) to The Midday Report broadcast on 702 https://buff.ly/gk3y0Kj and on CapeTalk https://buff.ly/NnFM3Nk For more from The Midday Report, go to https://buff.ly/BTGmL9H and find all the catch-up podcasts here https://buff.ly/LcbDdFI Subscribe to the 702 and CapeTalk daily and weekly newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567See omnystudio.com/listener for privacy information.

Catch Up on the latest leading news stories around the country with Mandy Wiener on Midday Report from 12:00 to 13:00See omnystudio.com/listener for privacy information.

(2) Bob Zimmerman details the December 21, 1968, launch and the historic trans-lunar injection that sent humans toward another planet for the first time. Zimmerman describes the Saturn 5 ride as surprisingly smooth compared to Gemini rockets, despite the primitive onboard computers that required manual data entry of long number strings. He shares Jim Lovell's perspective of the Earth shrinking until the entire Atlantic could be covered by a thumb. Crucially, the discussion reveals that while the Space Race remained competitive, NASA was unaware that Soviet Zond failures had secretly forced the cancellation of their own manned mission.1939

(7) Bob Zimmerman describes how the mission's return depended on a high-stakes Trans-Earth Injection burn, after which Jim Lovell famously radioed that "there is a Santa Claus." Zimmerman describes a navigation crisis where Lovellaccidentally wiped the computer's orientation data, forcing him to use a sextant and stars—ancient naval tools—to manually realign the ship. The guest marvels at the "double skip" re-entry, where the capsule bounced off the atmosphere at 25,000 miles per hour to slow down. Despite turning upside down in the Pacific, the crew returned safely, fulfilling a mission with odds NASA originally pegged at only 50/50.1959

Brady Hicks, WCW's Maestro, and Kathie Fitz take calls and talk the latest news. Live, Tuesday nights at 7:30PM ET on vocnation.com, it's IN THE ROOM! ITR features topics introduced by the panel, your calls, PWI's Brady Hicks, Kathie Fitz, and WCW's Maestro. Visit http://vocnation.com. Full Video Episode Available for only $3/mo at www.vocnation.com! Subscribers also get commercial free audio and video of Wrestling with History featuring Bill Apter and Ken Resnick, In the Room featuring PWI's Brady Hicks and former WCW Star the Maestro, No BS with The Bull Manny Fernandez, and more! VOC Nation takes you behind the scenes of your favorite moments in pro wrestling history. Notable show hosts include legendary pro wrestling journalist Bill Apter, former WWE/TNA star Shelly Martinez, former WWE and AWA broadcaster Ken Resnick, former WCW performer The Maestro, former TNA Impact talent Wes Brisco, Pro Wrestling Illustrated's Brady Hicks, independent pro wrestling and Fireball Run star Sassy Stephie, and more! Since 2010, VOC Nation has brought listeners into the minds of the biggest stars in pro wrestling and entertainment. Subscribe to the podcasts for free on most major directories, and visit http://vocnation.com for live programming. Subscribe to premium - only $3/mo - for commercial full commercial free audio and video episodes. Exclusive access to 50 years of Bill Apter's interview archives is available for a nominal charge. Learn more about your ad choices. Learn more about your ad choices. Visit podcastchoices.com/adchoices

All links here: ⁠https://hunterwilliamshealth.com/linksSS-31 continues to be one of my favorite peptides of all time, and the more data that comes out on it, the more I think every person over 25 has a use case for it.In this masterclass, I'm breaking down everything I know about SS-31. We cover what it actually does at the cellular level, why it's the first FDA-approved mitochondrial peptide, and why it works differently than almost every other peptide out there. No receptor binding. It goes inside your cells, binds to cardiolipin, and stabilizes the structure of your mitochondria.I walk through the three dosing tiers I use with people, my take on cycling, why I run SS-31 before MOTS-c, how to stack it with GLPs, GH peptides, and the healing peptides, and what to actually track when you're on it. I also cover the troubleshooting stuff people ask me about constantly. Why don't I feel anything? Should I cycle? What about the headaches in the first two weeks?If you're a clinician or just researching for yourself, this is the complete user's guide.For entertainment purposes only.Timestamps00:00 Intro01:00 What this masterclass covers03:18 Why SS-31 matters and what makes it different03:46 FDA approval and the Forzenity brand name04:50 Peptide foundations and how SS-31 is made05:52 The SS-31 sequence and the Seto-Schiller naming origin06:40 Mitochondria 101 and why ATP matters07:28 Mitochondrial dysfunction across chronic disease08:34 Cardiolipin, cristae, and Barth syndrome09:34 Why SS-31 is not a direct antioxidant10:46 How SS-31 actually works (the upstream Godfather effect)11:12 Why no receptor means no desensitization13:36 Who SS-31 is for (mid-30s, athletes, post-illness, metabolic dysfunction)14:24 Who should skip it15:34 The three-tier dosing ladder16:54 The FDA-approved 40mg dose and diminishing returns19:08 Dosing by goal (longevity, performance, recovery, healing)19:48 Cycling logic and the 8-12 week framework20:22 When to dose (morning vs night)21:24 What to expect and when (week-by-week timeline)22:20 Why cycle if it doesn't desensitize24:24 SS-31 before MOTS-c (the structural engineer vs operations manager)26:18 Reconstitution and injection technique28:22 What to track (subjective markers and biomarkers)29:18 Stacking with MOTS-c, Humanin, BPC, GH peptides, and GLPs31:28 Stacking for cognition and visceral fat32:26 Troubleshooting "I don't feel anything"33:54 Injection site reactions34:36 When to discontinue and the first-two-week headache window35:52 FAQ (legality, MitoQ comparison, oral routes, intranasal)36:54 Use cases (weight loss, long COVID, athletic performance, TRT, kids)37:54 Research grade vs pharmaceutical cost difference38:22 Future outlook (AMD, sarcopenia, SBT-272, oral bioavailability)40:30 Final thoughts and where SS-31 sits in the broader picture42:20 Closing

This episode features Chris Cavanaugh discussing equitable care for patients with substance use history, focusing on harm reduction, stigma, and best practices for infusion therapy across various settings.

Please see https://www.pfi.sr/HYMPAVZI_PI  for Full PI​ #HYMPAVZISponsored William S. Somers, Ph.D. is a biotherapeutics research and development leader with more than 30 years of experience across biotechnology and pharmaceutical organizations, including Pfizer.​ As a scientist living with hemophilia, Dr. Somers played a key role in driving the patient-centric and purposeful design of HYMPAVZI (marstacimab-hncq). This episode will explore how the patient perspective influenced the scientific journey, with a special focus on Will's research and why it was personally important for him to bring HYMPAVZI to people with hemophilia. To learn more and for safety information, visit HYMPAVZI.com.​ This post is directed to a U.S. audience and may not be suitable outside of the U.S. This video is intended to be viewed as it was originally produced in partnership with Pfizer. Remember, this content is for educational purposes only and is not intended to replace discussions with a healthcare provider.​ PP-HYM-USA-1071​ Show Notes:​ For prescribing information visit pfi.sr/HYMPAVZI_PI​ For information on how to navigate your treatment journey visit the shared decision-making guide here. Listen and subscribe where you get your podcasts!​ #Hemophilia HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HYMPAVZI safely and effectively. See full prescribing information for HYMPAVZI. HYMPAVZI (marstacimab-hncq) injection, for subcutaneous use Initial U.S. Approval: 2024 INDICATIONS AND USAGE HYMPAVZI is a tissue factor pathway inhibitor (TFPI) antagonist indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with: hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or hemophilia B (congenital factor IX deficiency) without factor IX inhibitors. DOSAGE AND ADMINISTRATION See Full Prescribing Information for important dosing and administration instructions.  The recommended dosage of HYMPAVZI is: Loading dose: 300 mg (two 150 mg injections) by subcutaneous injection Maintenance dose: One week after the loading dose, initiate maintenance dosing of 150 mg every week by subcutaneous injection on the same day each week, at any time of day. Dose adjustment to 300 mg subcutaneous injection weekly can be considered. Factor VIII and factor IX products can be administered for the treatment of breakthrough bleeds in patients receiving HYMPAVZI. Do not use additional doses of HYMPAVZI to treat breakthrough bleeds.  Temporarily discontinue HYMPAVZI before major surgery.  DOSAGE FORMS AND STRENGTHS Injection: 150 mg/mL in a single-dose prefilled syringe  Injection: 150 mg/mL in a single-dose prefilled pen  CONTRAINDICATIONS None. WARNINGS AND PRECAUTIONS Thromboembolic Events: Thromboembolic events may occur. Interrupt HYMPAVZI prophylaxis if symptoms occur. Hypersensitivity: Hypersensitivity reactions may occur. In the event of a severe allergic reaction, discontinue HYMPAVZI. Embryofetal Toxicity: May cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and to use effective contraception. ADVERSE REACTIONS Adverse reactions reported in ≥3% of HYMPAVZI-treated patients were injection site reaction, headache, and pruritus.  To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 12/2025

Soca Injection (Classic Soca) #1 by Dj Sheldon Papp

Join our free community, The Women's Peptide Collective, click the Skool link to become a member and to connect, learn, and collaborate. https://www.skool.com/womens-peptide-collective-9663Go to https:thepeptique.com/ to get all your research peptides. As a loyal listener use the discount code POD15 to get 15% off the entire line of products.Have questions? Feel free to reach out to me: tarawest@westwellnessatx.comWant the free peptide guide? Email me tarawest@westwellnessatx.com and comment Guide and I'll shoot it right over!Follow me on instagram AND TikTOk @westwellnessatxStay in touch add your email to the list ! https://form.jotform.com/25336471779006In this Q&A episode of the West Wellness & Longevity podcast, we're breaking down some of your most asked questions around peptides and functional wellness — including PCOS support, GHK-Cu cycling, injection site reactions and lumps, recovery peptides, hair and skin health, and how different peptides may fit into a long-term wellness strategy and more!This podcast is intended for educational and informational purposes only. The compounds and peptides discussed are research compounds and are not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease unless otherwise stated. Nothing in this episode should be interpreted as medical advice or as a substitute for guidance from a qualified healthcare professional. Always consult your licensed healthcare provider before making decisions related to your health, wellness, medications, or research protocols. Any dosing, protocol, or research discussion reflects anecdotal reports, published research, and theoretical mechanisms only. Products discussed are intended for laboratory research purposes only and not for human consumption.

Champions League baby! What a way to end the league season (effectively) and send us into a European final. These boys are heroes. The squad gets weaker each year and they still scale new heights. Even Austin MacPhee is getting praise again. But Liverpool are a mess and perhaps MacAllister sums that up right now. Hosted on Acast. See acast.com/privacy for more information.

In this episode, Afif and Anne take a deep dive into vitamin K at birth and the growing wave of misinformation surrounding it online. They explore why newborn babies are naturally low in vitamin K, how clotting works, and what vitamin K deficiency bleeding (VKDB) actually is. The discussion covers the differences between intramuscular and oral vitamin K, why the injection remains the most reliable protection, and the devastating consequences VKDB can have, including brain bleeding and death. Along the way, they unpack some of the most common myths circulating on social media, from claims about “toxins” and cancer to misconceptions around breastfeeding and “natural” birth. As always, the episode combines evidence-based medicine with honesty, humour, and practical conversations about how healthcare professionals and parents can navigate fear, risk, and misinformation together. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, Afif and Anne take a deep dive into vitamin K at birth and the growing wave of misinformation surrounding it online. They explore why newborn babies are naturally low in vitamin K, how clotting works, and what vitamin K deficiency bleeding (VKDB) actually is. The discussion covers the differences between intramuscular and oral vitamin K, why the injection remains the most reliable protection, and the devastating consequences VKDB can have, including brain bleeding and death. Along the way, they unpack some of the most common myths circulating on social media, from claims about “toxins” and cancer to misconceptions around breastfeeding and “natural” birth. As always, the episode combines evidence-based medicine with honesty, humour, and practical conversations about how healthcare professionals and parents can navigate fear, risk, and misinformation together. Learn more about your ad choices. Visit megaphone.fm/adchoices

Daniel Wyrzykowski is a Product Manager at Mend.io. In this episode, he joins host Paul John Spaulding to discuss prompt injection, including what it is, whether it's the new SQL injection, and more. Securing The Build is brought to you by Mend.io, the leading application security solution, helping organizations reduce application risk efficiently. To learn more about our sponsor, visit https://mend.io.

More than six square miles of an aquifer under Montana's Rocky Mountain Front has been removed from federal protections and slated for wastewater. The change comes despite overwhelming opposition from the local community.

Welcome to a packed Wednesday edition of What The Truck?!? Hosts Malcolm Harris and Michael Vincent are back on the set for a family reunion-style episode featuring industry heavyweights and groundbreaking tech. First, the "Nostradamus" of freight, Ryan Schreiber (CGO of Metafora), joins the show to tackle a fascinating new trend: the Ozempic effect on logistics. We dive into whether GLP-1 medications are actually making truckloads lighter and how shifting consumer preferences—from "junk food" to whole foods—are fundamentally altering freight volumes and produce seasons. Then, we welcome back a familiar face, Kaylee Nix, now Head of Communications at Bot Auto. Kaylee breaks down their historic achievement: delivering America's first fully humanless commercial truckload on a public highway. We get into the nitty-gritty of "Transportation as a Service" and why they consider themselves a trucking company first and a tech company second. ⁠Watch on YouTube⁠ ⁠Visit our sponsor - TAYLOR AND MARTIN⁠ ⁠Subscribe to the WTT newsletter⁠ ⁠Apple Podcasts⁠ ⁠Spotify⁠ ⁠More FreightWaves Podcasts⁠ #WHATTHETRUCK #FreightNews #supplychain Learn more about your ad choices. Visit megaphone.fm/adchoices

Welcome to a packed Wednesday edition of What The Truck?!? Hosts Malcolm Harris and Michael Vincent are back on the set for a family reunion-style episode featuring industry heavyweights and groundbreaking tech. First, the "Nostradamus" of freight, Ryan Schreiber (CGO of Metafora), joins the show to tackle a fascinating new trend: the Ozempic effect on logistics. We dive into whether GLP-1 medications are actually making truckloads lighter and how shifting consumer preferences—from "junk food" to whole foods—are fundamentally altering freight volumes and produce seasons. Then, we welcome back a familiar face, Kaylee Nix, now Head of Communications at Bot Auto. Kaylee breaks down their historic achievement: delivering America's first fully humanless commercial truckload on a public highway. We get into the nitty-gritty of "Transportation as a Service" and why they consider themselves a trucking company first and a tech company second. Watch on YouTube Visit our sponsor - TAYLOR AND MARTIN Subscribe to the WTT newsletter Apple Podcasts Spotify More FreightWaves Podcasts #WHATTHETRUCK #FreightNews #supplychain Learn more about your ad choices. Visit megaphone.fm/adchoices

Chris Hughen sat down with Ben Steele-Turner to discuss all things osteoarthritis. We dive into nine common myths and misconceptions of osteoarthritis, including imaging findings and pain levels, exercise, weight management, wear and tear, and much more. Watch the full episode: https://youtu.be/NaNPP69FV3Q  Episode Resources: Ben's Instagram Overview of OA - https://pubmed.ncbi.nlm.nih.gov/39755397/ Radiographic vs Symptomatic OA - https://link.springer.com/article/10.1007/s00256-026-05204-4 Knee OA Trajectories: Pain - https://pubmed.ncbi.nlm.nih.gov/32882828/  Structural - https://pubmed.ncbi.nlm.nih.gov/32491247/ Exercise therapy for knee OA - https://pubmed.ncbi.nlm.nih.gov/37346776/ - Systems model - https://pmc.ncbi.nlm.nih.gov/articles/PMC4340713/ - Muscle strength and KOA risk https://pubmed.ncbi.nlm.nih.gov/36562820/ Injection therapies narrative review - https://pmc.ncbi.nlm.nih.gov/articles/PMC11938051/ Likelihood of needing TJR - https://pubmed.ncbi.nlm.nih.gov/28493422/ Weather and Symptomatic OA - https://pubmed.ncbi.nlm.nih.gov/37078741/ Weight Management: https://pubmed.ncbi.nlm.nih.gov/39233046/https://pubmed.ncbi.nlm.nih.gov/41276008/ https://pubmed.ncbi.nlm.nih.gov/24632294/ --- Membership: https://e3rehab.com/premium/  Mentoring: https://e3rehab.com/mentoring/ Coaching & Consultations: https://e3rehab.com/coaching/  Rehab & Performance Programs: https://e3rehab.com/programs/  Resource Guides: https://e3rehab.com/resource-guides  Newsletter: https://e3rehab.ck.page/19eae53ac1  --- Follow Us: YouTube: https://www.youtube.com/e3rehab  Instagram: https://www.instagram.com/e3rehab/ X: https://x.com/E3Rehab  LinkedIn: https://www.linkedin.com/company/e3rehab/  Facebook: https://www.facebook.com/e3rehab  --- Podcast Sponsor: Vivo Barefoot: Get 20% off all shoes! - https://www.vivobarefoot.com/e3rehab --- @dr.surdykapt @tony.comella @dr.nicolept @chrishughen @nateh_24 --- This episode was produced by Kody Hughes

In episode 185 of Cybersecurity Where You Are, Sean Atkinson sits down with Brian Calkin, Chief Technology and Innovation Officer at the Center for Internet Security® (CIS®); Theodore "TJ" Sayers, Senior Director of Threat Intelligence at CIS; and Kyle Leonard, Cyber Threat Intelligence Analyst at CIS. Together, they use a risk perspective to discuss artificial intelligence (AI) prompt injection and how to defend against it.Here are some highlights from our episode:00:49. A definition of AI prompt injection for businesses and executives02:16. Brian on his role of guiding AI implementation at CIS03:12. Understanding the urgency surrounding AI prompt injection as a security risk05:32. Signals and trends indicative of threat actors attempting to weaponize prompt injection07:10. How AI prompt injection differs from traditional input validation vulnerabilities11:13. Early indicators that cyber threat intelligence (CTI) teams can monitor15:00. The need to treat AI as a new identity in any enterprise implementation strategy17:10. Understanding the difference: AI safety vs. AI security20:36. Foundational, practical AI security that extends across all sectors24:55. How CIS manages risk and supports the opportunity around the use of AI28:25. The long-term promise of AI-driven vulnerability discovery grounded in fundamentals34:48. Recommendations for piercing through the marketing hype surrounding AIResourcesPrompt Injections: The Inherent Threat to Generative AINew CIS Report Warns Prompt Injection Attacks Pose Growing Risk to Generative AIEpisode 182: Striking a Balance on an AI Adoption JourneyEpisode 120: How Contextual Awareness Drives AI GovernanceMythos AI: What Actually Matters for Cybersecurity LeadersApplying the CIS Controls to Real‑World AI EnvironmentsAn Examination of Generative AI and Physical Threat PlanningAI Playbooks for SLTT Cybersecurity LeadersIf you have some feedback or an idea for an upcoming episode of Cybersecurity Where You Are, let us know by emailing podcast@cisecurity.org.

In this episode of the ICS Podcast, we explore how botulinum toxin (BoNT‑A) injection techniques for overactive bladder (OAB) are evolving—and why injection location, depth, and template may matter more than ever.Hosted by Juan Peñafiel and Shannon Wallace, the discussion brings together two internationally recognised experts: Benoit Peyronnet (Urologist) and Michael Kennelly (Neurourologist). Together, they examine the growing evidence behind trigonal and trigone‑sparing injection strategies, challenging long‑held dogmas around reflux risk and urinary retention.Key topics include:Why and when to consider trigonal or predominantly trigonal injection templatesHow injection depth, volume, and number of sites influence outcomesStrategies to reduce the risk of urinary retention while maintaining efficacyDifferences in approach for idiopathic vs neurogenic OABPractical tips for training, technique, and tailoring treatment to individual patientsThe conversation also reflects on gaps in the current evidence base, what future trials are still needed, and how clinicians can safely adapt their practice today. ICS PodcastThrough its annual meeting and journal, the International Continence Society (ICS) has been advancing multidisciplinary continence research and education worldwide since 1971.Over 3,000 Urologists, Uro-gynaecologists, Physiotherapists, Nurses and Research Scientists make up ICS, a thriving society dedicated to incontinence and pelvic floor disorders. The Society is growing every day and welcomes you to join us. If you join today, you'll enjoy substantial discounts on ICS Annual Meeting registrations and free journal submissions.Joining ICS is like being welcomed into a big family. Get to know the members and become involved in a vibrant, supportive community of healthcare professionals, dedicated to making a real difference to the lives of people with incontinence.

Seth and Sean dive into each of the Texans' draft picks from this class, give credit where it's due in Acknowledge Me, and see who Cooper Petagna from CBS Sports has the Texans picking and where he has them picking in 2027 in today's Mock Draft Injection.

Send us Fan MailDr. David Sas, pediatric nephrologist at Mayo Clinic, joins Ben to discuss primary hyperoxaluria type 1 — a rare but devastating genetic disease where the liver overproduces oxalate, flooding the kidneys with crystals and leading to end-stage kidney failure in roughly 60% of patients, historically requiring both a liver and kidney transplant. He presents 60-month long-term extension data on Lumasiran, an siRNA-based therapy that suppresses oxalate production at its source — showing that urinary oxalate drops rapidly within the first three months and stays down with quarterly injections, potentially changing the trajectory of this disease forever. He also issues a direct call to urologists and nephrologists everywhere: if your patient has recurrent calcium oxalate stones, check a 24-hour urine — because primary hyperoxaluria is almost certainly being missed.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Seth and Sean discuss what Nick Caserio and Keylan Rutledge himself say Rutledge brings to the Texans, lay out some big picture draft takeaways, and see what Josh Edwards has the Texans doing at 38 and 59 in the mock draft injection.

Seth and Sean see what Josh Edwards of CBS Sports has the Texans doing at 38 and 59 tonight in the Mock Draft Injection.

Seth and Sean see who Eric Edholm, Bucky Brooks, and Brett Kollman each have the Texans picking at #28 in their respective mock drafts in today's Mock Draft Injection.

Seth and Sean discuss their frustration with the Rockets, their problems being larger than their injured players, what Will Anderson Jr. had to say about getting his bag and his relationship with DeMeco, react to what Mike Vrabel had to say to the media, and see who Eric Edholm, Bucky Brooks and Brett Kollman each have the Texans picking in today's Mock Draft Injection.

Seth and Sean discuss what Chad Reuter of NFL.com has the Texans doing in the first few rounds in today's Mock Draft Injection.

Seth and Sean dive into what DeMeco Ryans had to say about his approach to the rookies, Tank Dell's importance, and evaluating defensive linemen, look at the odds as to which position the Texans will draft, react to Dr. David Chao saying he thinks Kevin Durant could be back for game 2, and see who Chad Reuter has the Texans picking in today's Mock Draft Injection.

Seth and Sean take a deep dive into Will Anderson getting his extension, discuss Dexter Lawrence being traded to the Bengals, give credit in Acknowledge Me, and see what Bryant McFadden has the Texans doing with the 28th pick in the Mock Draft Injection.

Seth and Sean assess what Bryant McFadden from CBSSports.com has the Texans doing with the 28th overall pick in today's Mock Draft Injection.

Seth and Sean see what Adam Rank from NFL.com thinks the Texans should do with the 28th overall pick in today's Mock Draft Injection.

Seth and Sean get prepped for tomorrow's playoff matchup by laying out 5 reasons they hate the Lakers, react to what Texans OL Trent Brown had to say on "The Set with Terron Armstead" about the O-line additions and Ersery's 2nd year, and see what Adam Rank has the Texans doing at #28 in the Mock Draft Injection.

The OWASP Top 10 just got a fresh update, and there are some big changes: supply chain attacks, exceptional condition handling, and more. Tanya Janca is back on Talk Python to walk us through every single one of them. And we're not just talking theory, we're going to turn Claude Code loose on a real open source project and see what it finds. Let's do it. Episode sponsors Temporal Talk Python Courses Links from the show DevSec Station Podcast: www.devsecstation.com SheHacksPurple Newsletter: newsletter.shehackspurple.ca owasp.org: owasp.org owasp.org/Top10/2025: owasp.org from here: github.com Kinto: github.com A01:2025 - Broken Access Control: owasp.org A02:2025 - SecuA02 Security Misconfiguration: owasp.org ASP.NET: ASP.NET A03:2025 - Software Supply Chain Failures: owasp.org A04:2025 - Cryptographic Failures: owasp.org A05:2025 - Injection: owasp.org A06:2025 - Insecure Design: owasp.org A07:2025 - Authentication Failures: owasp.org A08:2025 - Software or Data Integrity Failures: owasp.org A09:2025 - Security Logging and Alerting Failures: owasp.org A10 Mishandling of Exceptional Conditions: owasp.org https://github.com/KeygraphHQ/shannon: github.com anthropic.com/news/mozilla-firefox-security: www.anthropic.com generalpurpose.com/the-distillation/claude-mythos-what-it-means-for-your-business: www.generalpurpose.com Python Example Concepts: blobs.talkpython.fm Watch this episode on YouTube: youtube.com Episode #545 deep-dive: talkpython.fm/545 Episode transcripts: talkpython.fm Theme Song: Developer Rap

Seth and Sean react and assess what Mel Kiper Jr. of ESPN has the Texans doing in his most recent 3-round mock in today's Mock Draft Injection.

Seth and Sean dive into what Texans GM Nick Caserio had to say yesterday when they asked about how other teams view him and players around the league wanting to play for DeMeco Ryans, and see what Mel Kiper Jr. has the Texans doing in today's Mock Draft Injection.

Seth and Sean see what Dane Brugler of the Athletic has the Texans doing in all 7 rounds in today's Mock Draft Injection.

2. Zimmerman details the December 1968 launch and the historic trans-lunar injection. He describes the crew's reliance on primitive computers, requiring manual data entry for critical maneuvers. As they accelerated toward the moon, Jim Lovell observed the Earth shrinking, marking humanity's first departure from Earth orbit. (2)1870